A Study to Evaluate the Efficacy, Safety, and Tolerability of VIM0423 in Individuals With Isolated Dystonia

ClinicalTrials.gov ID

NCT07304089

Lead Sponsor

Vima TherapeuticsINDUSTRY

Overall Status

Recruiting

Study Type

Interventional

Phase

Phase 2

Enrollment

100Estimated

Last Update Posted

Aug 4, 2026Actual

Start Date

Feb 5, 2026Actual

Primary Completion Date

Mar 2027Estimated

Completion Date

May 2027Estimated

Official Title

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of VIM0423 in Individuals With Isolated Dystonia (Stride Dystonia)

Brief Summary

Stride Dystonia is a randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of VIM0423 in individuals with isolated dystonia.

The main objectives of this clinical trial are to determine the following:

• Does VIM0423 therapy improve dystonia symptoms compared to placebo?
• Is VIM0423 well tolerated in individuals with isolated dystonia? and
• Do the therapeutic effects of VIM0423 confer improvements on daily function and quality of life?

Detailed Description

Isolated dystonia, previously referred to as primary dystonia, is a rare movement disorder subclassified according to parts of the body affected. Approximately 160,000 individuals in the United States are affected. Dystonia is characterized by sustained muscle contractions which cause abnormal movements and/or postures. These can be patterned, twisting, or tremulous.

Botulinum toxins (BoNT) are the only approved drug products in the US for the treatment of dystonia; however, these injections are only approved for individuals with a diagnosis of cervical (neck) dystonia or blepharospasm (eye lid) and act locally to weaken affected muscles. There are no approved treatment options for approximately 50% of individuals with other subtypes of isolated dystonia that affect more than one body part, and there are no approved oral treatments for dystonia.

VIM0423 is being developed as a once-daily oral medication that will address the root cause of dystonia, which is known to be a chemical imbalance in specific brain regions. As such, VIM0423 is intended to treat most people with isolated dystonia, regardless of the number of body parts affected.

Stride Dystonia (Study VIM0423-201) is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study designed to assess the efficacy, safety, and tolerability of VIM0423 in adults with isolated dystonia that affects two or more body regions. Up to 120 individuals will be enrolled in the trial.

Participants will be randomized (1:1) to receive either VIM0423 or matching placebo (up to 6 pills a day, taken before bed each evening) for 16 weeks. The Investigator and Participant will not know what patients are receiving VIM0423 or placebo, but that information will be available if needed.

The total time of participation in the trial is up to 32 weeks and requires 6 in person visits. The study schedule includes Screening and Baseline (up to 14 weeks, 2 visits), Dose Titration, Dose Maintenance, Dose Taper (16 weeks, 3 Visits), and Safety follow-up (2 weeks, 1 Visit).

Assessments of changes in dystonia including video recordings will be made by study personnel. Clinical labs, EKGs, and Adverse events will be monitored throughout the study. Participants will be asked to perform self-assessments of their dystonia and its impact on their activities of daily living.

• Dystonia

• VIM0423
• VIM0423 Placebo

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Participant must be male or nonpregnant female between 18 and 65 years of age (inclusive) at Visit 1 (Screening).
• The participant has a clinical diagnosis of isolated dystonia for at least one year prior to Visit 1 (Screening); has two or more body regions affected by dystonia at Visit 1 (Screening); and has been confirmed by Investigator and Enrollment Authorization Committee.
• The participant may be untreated with BoNT; OR if the participant is being treated with BoNT as part of their standard of care for dystonia, they must meet protocol-specified criteria.
• The participants must meet protocol-specified requirements for baseline scores on the BFM and CGI-S.

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

Quadruple

Lead Sponsor

Vima TherapeuticsINDUSTRY

clinicaltrials@vimatx.com617-430-7027

clinicaltrials@vimatx.com617-430-7027

clinicaltrials@vimatx.com617-430-7027

clinicaltrials@vimatx.com617-430-7027

clinicaltrials@vimatx.com617-430-7027

clinicaltrials@vimatx.com617-430-7027

clinicaltrials@vimatx.com617-430-7027

clinicaltrials@vimatx.com617-430-7027

clinicaltrials@vimatx.com617-430-7027

clinicaltrials@vimatx.com617-430-7027

clinicaltrials@vimatx.com617-430-7027

clinicaltrials@vimatx.com617-430-7027

clinicaltrials@vimatx.com617-430-7027

clinicaltrials@vimatx.com617-430-7027

clinicaltrials@vimatx.com617-430-7027

clinicaltrials@vimatx.com617-430-7027

clinicaltrials@vimatx.com617-430-7027

clinicaltrials@vimatx.com617-430-7027

clinicaltrials@vimatx.com617-430-7027

clinicaltrials@vimatx.com617-430-7027

clinicaltrials@vimatx.com617-430-7027

clinicaltrials@vimatx.com617-430-7027

clinicaltrials@vimatx.com617-430-7027

clinicaltrials@vimatx.com617-430-7027

clinicaltrials@vimatx.com617-430-7027

clinicaltrials@vimatx.com617-430-7027

clinicaltrials@vimatx.com617-430-7027

clinicaltrials@vimatx.com617-430-7027

clinicaltrials@vimatx.com617-430-7027

clinicaltrials@vimatx.com617-430-7027

clinicaltrials@vimatx.com617-430-7027

• A Study to Evaluate the Efficacy, PK, Safety, and Tolerability of VIM0423 in Adults With Parkinson's Disease Tremor Insufficiently Responsive to Dopaminergic Therapy

  NCT07804615

  RecruitingInterventionalPhase 2Updated Sep 11, 2026
• Study of the Oral Treatment MTR-601 in Cervical Dystonia

  NCT06830642

  SuspendedInterventionalPhase 2Updated Dec 12, 2025
• Segmental Muscle Vibration on Pain in Patients With Primary Cervical Dystonia

  NCT06748846

  Active, not recruitingInterventionalNot ApplicableUpdated Dec 27, 2024
• A Study to Assess Vamorolone in Becker Muscular Dystrophy (BMD)

  NCT05166109

  CompletedInterventionalPhase 2Updated Sep 18, 2025
• An Observational Study of Individuals With Isolated Dystonia

  NCT07111663

  RecruitingObservationalUpdated Aug 19, 2026
• Multi-Target Pallidal and Thalamic Deep Brain Stimulation for Hemi-Dystonia

  NCT02982304

  Unknown statusInterventionalPhase 1Updated Nov 2, 2020